Arete Wealth Advisors’s Biolase, Inc. BIOL Stock Holding History

Arete Wealth Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9	Closed	-$8K	–	579
2022 Q1	$8K	Buy	9 +4	+80%	+$3.69K	﹤0.01%	506
2021 Q4	$5K	Buy	+5	New	+$6.31K	﹤0.01%	502

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arete Wealth Advisors's BIOL Position: Q2 2022 in Review

Arete Wealth Advisors sold out of Biolase, Inc. (BIOL) in Q2 2022, closing a stake of 9 shares — an estimated $8K sold.

Arete Wealth Advisors first reported a position in BIOL in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q1 2022. 16 funds tracked by Wall St. Rank hold BIOL as of Q2 2022.

Arete Wealth Advisors reported no remaining Biolase, Inc. position as of Q2 2022 after selling out during the quarter.
Arete Wealth Advisors sold 9 Biolase, Inc. shares in Q2 2022, an estimated $8K.
Arete Wealth Advisors first reported a position in Biolase, Inc. in Q4 2021 and held it in 2 quarters.
Arete Wealth Advisors's Biolase, Inc. position peaked at $8K in Q1 2022.
16 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2022.

Based on Arete Wealth Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.